Iterum Therapeutics 

$0.07
0
+$0.02+44.76% Tuesday 07:49

Statistics

Day High
0.07
Day Low
0.06
52W High
-
52W Low
-
Volume
5,948,349
Avg. Volume
-
Mkt Cap
3.25M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

20MayExpected
Q3 2025
Next
Next
-0.16
-0.14
-0.11
-0.09
Expected EPS
-0.1
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-49.55MNet Income

Analyst Ratings

$0.00Average Price Target
The highest estimate is 0.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
0%
Hold
100%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ITRM.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap140.15B
Pfizer is a major pharmaceutical company that competes with Iterum Therapeutics in the development and marketing of antibiotics and treatments for infections, a key area for Iterum.
Merck
MRK
Mkt Cap214.76B
Merck & Co., Inc. is involved in the discovery, development, manufacturing, and marketing of pharmaceuticals, including anti-infectives, directly competing with Iterum's product offerings.
GSK
GSK
Mkt Cap94.51B
GlaxoSmithKline plc focuses on creating vaccines and antibiotics, competing with Iterum Therapeutics in the antibiotics market.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie Inc. operates in the pharmaceuticals sector, including the development of anti-infective therapies, making it a competitor to Iterum Therapeutics.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson, through its pharmaceutical segment, develops and sells products in various therapeutic areas, including infectious diseases, competing with Iterum.
Novartis
NVS
Mkt Cap237.61B
Novartis AG is a global healthcare company that has a strong presence in the development of drugs for infectious diseases, competing with Iterum Therapeutics.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca PLC is involved in the discovery and development of antibiotics, directly competing with Iterum Therapeutics in the anti-infective space.
Sanofi
SNY
Mkt Cap124.45B
Sanofi is a global life sciences company that focuses on healthcare solutions, including antibiotics, making it a competitor to Iterum Therapeutics.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap23.49B
Teva Pharmaceutical Industries Limited operates in generic and specialty medicines, including the development of anti-infective drugs, competing with Iterum.
Seres Therapeutics
MCRB
Mkt Cap140.95M
Seres Therapeutics, Inc. focuses on microbiome therapeutics for infections and other conditions, representing a novel competition to Iterum Therapeutics in the infectious disease sector.

About

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.
Show more...
CEO
ISIN
IE000TTOOBX0

Listings

0 Comments

Share your thoughts

FAQ

What is Iterum Therapeutics stock price today?
The current price of ITRM.BOATS is $0.07 USD — it has increased by +44.76% in the past 24 hours. Watch Iterum Therapeutics stock price performance more closely on the chart.
What is Iterum Therapeutics stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange Iterum Therapeutics stocks are traded under the ticker ITRM.BOATS.
What is Iterum Therapeutics market cap?
Today Iterum Therapeutics has the market capitalization of 3.25M
When is the next Iterum Therapeutics earnings date?
Iterum Therapeutics is going to release the next earnings report on May 20, 2026.
What is Iterum Therapeutics revenue for the last year?
Iterum Therapeutics revenue for the last year amounts to 0 USD.
What is Iterum Therapeutics net income for the last year?
ITRM.BOATS net income for the last year is -49.55M USD.
When did Iterum Therapeutics complete a stock split?
Iterum Therapeutics has not had any recent stock splits.